We are live on ! Find out more
ONCT

Oncternal Therapeutics, Inc. Common Stock
ONCT

Delisted

ONCT was delisted on the 2nd of December, 2024.

Back to rankings

36 hedge funds and large institutions have $7.51M invested in Oncternal Therapeutics, Inc. Common Stock in 2016 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

8% less funds holding

Funds holding: 39 → 36 (-3)

29% less capital invested

Capital invested by funds: $10.6M → $7.51M (-$3.06M)

50% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 6

57% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 7

Holders
36
Holders Change
-3
Holders Change %
-7.69%
% of All Funds
0.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
7
Closed
6
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
+$27K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$216K
2
DT
Diversified Trust
Tennessee
+$20.8K
3
Citadel Advisors
Citadel Advisors
Florida
+$13K
4
Group One Trading
Group One Trading
Illinois
+$4.33K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.6K

Top Sellers

Rank Fund Capital Flow
1
SIM
Spark Investment Management
New York
-$44K
2
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$29.5K
3
VKH
Virtu KCG Holdings
New York
-$15K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$14K
5
Morgan Stanley
Morgan Stanley
New York
-$13K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$5K – – –
Wells Fargo
27
Wells Fargo
California
$5K – – –
Manulife (Manufacturers Life Insurance)
28
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$4K – – –
Morgan Stanley
29
Morgan Stanley
New York
$3K -$13K -15 -79%
UBS Group
30
UBS Group
Switzerland
$3K -$867 -1 -17%
Citigroup
31
Citigroup
New York
$3K – – –
JIR
32
James Investment Research
Ohio
$3K – – –
TDC
33
Thompson Davis & Co
Virginia
$3K – – –
AIG
34
American International Group
New York
$1K – – –
Creative Planning
35
Creative Planning
Kansas
$1K – – –
Geode Capital Management
36
Geode Capital Management
Massachusetts
$175 -$867 -1 -0.4%
SIM
37
Spark Investment Management
New York
– -$44K -46 Closed
VKH
38
Virtu KCG Holdings
New York
– -$15K -16 Closed
Susquehanna International Group
39
Susquehanna International Group
Pennsylvania
– -$14K -14 Closed
IA
40
IFP Advisors
Florida
– -$8K -8 Closed
Simplex Trading
41
Simplex Trading
Illinois
– -$2K -2 Closed
TRCT
42
Tower Research Capital (TRC)
New York
– -$1K -1 Closed
1
2

ONCT Hedge Fund Activity: Q1 2016 in Review

36 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q1 2016, worth a combined $7.51M — down 29% from $10.6M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of ONCT and 3 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 3 added.

The largest buyer was BVF Inc, adding an estimated $216K. The largest seller was Spark Investment Management, exiting entirely with an estimated $44K sold.

  • 36 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q1 2016, down from 39 in Q4 2015.
  • Funds reported $7.51M of Oncternal Therapeutics, Inc. Common Stock stock for Q1 2016, down 29% quarter-over-quarter.
  • 3 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q1 2016 and 6 closed out, a net change of -3 holders.
  • The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q1 2016 was BVF Inc, an estimated $216K added.
  • The largest Oncternal Therapeutics, Inc. Common Stock seller in Q1 2016 was Spark Investment Management, an estimated $44K sold.

Based on aggregated 13F filings for Q1 2016.